The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.
复制标题
DOI:
10.1016/j.celrep.2021.110218
复制
发表时间:
2022-01-11
期刊:
影响因子:
8.8
通讯作者:
Sato K
中科院分区:
文献类型:
--
作者:
Kimura I;Kosugi Y;Wu J;Zahradnik J;Yamasoba D;Butlertanaka EP;Tanaka YL;Uriu K;Liu Y;Morizako N;Shirakawa K;Kazuma Y;Nomura R;Horisawa Y;Tokunaga K;Ueno T;Takaori-Kondo A;Schreiber G;Arase H;Genotype to Phenotype Japan (G2P-Japan) Consortium;Motozono C;Saito A;Nakagawa S;Sato K
SARS-CoV-2 Lambda, a variant of interest, has spread in some South American countries; however, its virological features and evolutionary traits remain unclear. In this study, we use pseudoviruses and reveal that the spike protein of the Lambda variant is more infectious than that of other variants due to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation, a unique 7-amino acid deletion in the N-terminal domain of the Lambda spike protein, is responsible for evasion from neutralizing antibodies and further augments antibody-mediated enhancement of infection. Although this mutation generates a nascent N-linked glycosylation site, the additional N-linked glycan is dispensable for the virological property conferred by this mutation. Since the Lambda variant has dominantly spread according to the increasing frequency of the isolates harboring the RSYLTPGD246-253N mutation, our data suggest that the RSYLTPGD246-253N mutation is closely associated with the substantial spread of the Lambda variant in South America. Kimura et al. reveal the characteristics of the SARS-CoV-2 Lambda variant of interest. Lambda spike is more infectious than that of other variants due to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation is responsible for evasion from neutralizing antibodies and further augments antibody-mediated enhancement of infection.
登录
查看更多内容
DOI:
10.1093/infdis/jiab368
发表时间:
2021-09-17
期刊:
The Journal of infectious diseases
影响因子:
--
作者:
Ferreira IATM;Kemp SA;Datir R;Saito A;Meng B;Rakshit P;Takaori-Kondo A;Kosugi Y;Uriu K;Kimura I;Shirakawa K;Abdullahi A;Agarwal A;Ozono S;Tokunaga K;Sato K;Gupta RK;CITIID-NIHR BioResource COVID-19 Collaboration, Indian SARS-CoV-2 Genomics Consortium;Genotype to Phenotype Japan (G2P-Japan) Consortium
通讯作者:
Genotype to Phenotype Japan (G2P-Japan) Consortium
影响因子:
64.5
作者:
Hoffmann M;Arora P;Groß R;Seidel A;Hörnich BF;Hahn AS;Krüger N;Graichen L;Hofmann-Winkler H;Kempf A;Winkler MS;Schulz S;Jäck HM;Jahrsdörfer B;Schrezenmeier H;Müller M;Kleger A;Münch J;Pöhlmann S
通讯作者:
Pöhlmann S
影响因子:
64.5
作者:
Garcia-Beltran, Wilfredo F.;Lam, Evan C.;Balazs, Alejandro B.
通讯作者:
Balazs, Alejandro B.
DOI:
10.1126/science.abi6226
发表时间:
2021-08-06
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Gobeil SM;Janowska K;McDowell S;Mansouri K;Parks R;Stalls V;Kopp MF;Manne K;Li D;Wiehe K;Saunders KO;Edwards RJ;Korber B;Haynes BF;Henderson R;Acharya P
通讯作者:
Acharya P
DOI:
10.1056/nejmoa2105000
发表时间:
2021-06-10
期刊:
The New England journal of medicine
影响因子:
--
作者:
Hacisuleyman E;Hale C;Saito Y;Blachere NE;Bergh M;Conlon EG;Schaefer-Babajew DJ;DaSilva J;Muecksch F;Gaebler C;Lifton R;Nussenzweig MC;Hatziioannou T;Bieniasz PD;Darnell RB
通讯作者:
Darnell RB